{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T09:21:14Z","timestamp":1772616074571,"version":"3.50.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T00:00:00Z","timestamp":1638230400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T00:00:00Z","timestamp":1638230400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s12020-021-02953-1","type":"journal-article","created":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T19:37:10Z","timestamp":1638301030000},"page":"883-888","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Speed of response to dopaminergic agents in prolactinomas"],"prefix":"10.1007","volume":"75","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6652-0725","authenticated-orcid":false,"given":"Camille","family":"Hage","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6495-2244","authenticated-orcid":false,"given":"Roberto","family":"Salvatori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,11,30]]},"reference":[{"key":"2953_CR1","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s11060-014-1386-5","volume":"117","author":"M Bergsneider","year":"2014","unstructured":"M. Bergsneider, L. Mirsadraei, W.H. Yong, N. Salamon, M. Linetsky, M.B. Wang, D.L. McArthur, A.P. Heaney, The pituitary stalk effect: is it a passing phenomenon? J. Neurooncol. 117, 477\u2013484 (2014)","journal-title":"J. Neurooncol."},{"key":"2953_CR2","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1210\/jc.2010-1692","volume":"96","author":"S Melmed","year":"2011","unstructured":"S. Melmed, F.F. Casanueva, A.R. Hoffman, D.L. Kleinberg, V.M. Montori, J.A. Schlechte, J.A. Wass, E. Society, Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab 96, 273\u2013288 (2011)","journal-title":"J. Clin. Endocrinol. Metab"},{"key":"2953_CR3","first-page":"168","volume":"85","author":"MR Drange","year":"2000","unstructured":"M.R. Drange, N.R. Fram, V. Herman-Bonert, S. Melmed, Pituitary tumor registry: a novel clinical resource. J. Clin. Endocrinol. Metab. 85, 168\u2013174 (2000)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2953_CR4","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.mehy.2008.08.030","volume":"72","author":"DC Skinner","year":"2009","unstructured":"D.C. Skinner, Rethinking the stalk effect: a new hypothesis explaining suprasellar tumor-induced hyperprolactinemia. Med. Hypotheses. 72, 309\u2013310 (2009)","journal-title":"Med. Hypotheses."},{"key":"2953_CR5","first-page":"1789","volume":"85","author":"BM Arafah","year":"2000","unstructured":"B.M. Arafah, D. Prunty, J. Ybarra, M.L. Hlavin, W.R. Selman, The dominant role of increased intrasellar pressure in the pathogenesis of hypopituitarism, hyperprolactinemia, and headaches in patients with pituitary adenomas. J. Clin. Endocrinol. Metab. 85, 1789\u20131793 (2000)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2953_CR6","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1055\/s-0030-1267991","volume":"119","author":"P Anagnostis","year":"2011","unstructured":"P. Anagnostis, F. Adamidou, S.A. Polyzos, Z. Efstathiadou, A. Panagiotou, M. Kita, Non-functioning pituitary adenomas: a single center experience. Exp. Clin. Endocrinol. Diabetes. 119, 314\u2013319 (2011)","journal-title":"Exp. Clin. Endocrinol. Diabetes."},{"key":"2953_CR7","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1530\/eje.1.02334","volume":"156","author":"OM Dekkers","year":"2007","unstructured":"O.M. Dekkers, S. Hammer, R.J. de Keizer, F. Roelfsema, P.J. Schutte, J.W. Smit, J.A. Romijn, A.M. Pereira, The natural course of non-functioning pituitary macroadenomas. Eur. J. Endocrinol. 156, 217\u2013224 (2007)","journal-title":"Eur. J. Endocrinol."},{"key":"2953_CR8","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1530\/EC-18-0065","volume":"7","author":"NM Vaninetti","year":"2018","unstructured":"N.M. Vaninetti, D.B. Clarke, D.A. Zwicker, C.E. Yip, B. Tugwell, S. Doucette, C. Theriault, K. Aldahmani, S.A. Imran, A comparative, population-based analysis of pituitary incidentalomas vs clinically manifesting sellar masses. Endocr. Connect 7, 768\u2013776 (2018)","journal-title":"Endocr. Connect"},{"key":"2953_CR9","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1210\/jcem-69-3-500","volume":"69","author":"I Pellegrini","year":"1989","unstructured":"I. Pellegrini, R. Rasolonjanahary, G. Gunz, P. Bertrand, S. Delivet, C.P. Jedynak, C. Kordon, F. Peillon, P. Jaquet, A. Enjalbert, Resistance to bromocriptine in prolactinomas. J. Clin. Endocrinol. Metab. 69, 500\u2013509 (1989)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2953_CR10","first-page":"18990","volume":"8","author":"F Zhang","year":"2015","unstructured":"F. Zhang, Y. Huang, C. Ding, G. Huang, S. Wang, The prevalence of hyperprolactinemia in non-functioning pituitary macroadenomas. Int. J. Clin. Exp. Med. 8, 18990\u201318997 (2015)","journal-title":"Int. J. Clin. Exp. Med."},{"key":"2953_CR11","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jocn.2014.07.020","volume":"22","author":"JS Cheng","year":"2015","unstructured":"J.S. Cheng, R. Salinas, A. Molinaro, E.F. Chang, S. Kunwar, L. Blevins, M.K. Aghi, A predictive algorithm for evaluating elevated serum prolactin in patients with a sellar mass. J. Clin. Neurosci. 22, 155\u2013160 (2015)","journal-title":"J. Clin. Neurosci."},{"key":"2953_CR12","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1111\/j.1365-2265.2006.02627.x","volume":"65","author":"N Karavitaki","year":"2006","unstructured":"N. Karavitaki, G. Thanabalasingham, H.C. Shore, R. Trifanescu, O. Ansorge, N. Meston, H.E. Turner, J.A. Wass, Do the limits of serum prolactin in disconnection hyperprolactinaemia need re-definition? A study of 226 patients with histologically verified non-functioning pituitary macroadenoma. Clin. Endocrinol. (Oxf). 65, 524\u2013529 (2006)","journal-title":"Clin. Endocrinol. (Oxf)."},{"key":"2953_CR13","doi-asserted-by":"publisher","first-page":"236","DOI":"10.20945\/2359-3997000000032","volume":"62","author":"L Vilar","year":"2018","unstructured":"L. Vilar, J. Abucham, J.L. Albuquerque, L.A. Araujo, M.F. Azevedo, C.L. Boguszewski, L.A. Casulari, M.B.C. Cunha Neto, M.A. Czepielewski, F.H.G. Duarte, M.D.S. Faria, M.R. Gadelha, H.M. Garmes, A. Glezer, M.H. Gurgel, R.S. Jallad, M. Martins, P.A.C. Miranda, R.M. Montenegro, N.R.C. Musolino, L.A. Naves, A. Ribeiro-Oliveira J\u00fanior, C.M.S. Silva, C. Viecceli, M.D. Bronstein, Controversial issues in the management of hyperprolactinemia and prolactinomas - An overview by the Neuroendocrinology Department of the Brazilian Society of Endocrinology and Metabolism. Arch. Endocrinol. Metab 62, 236\u2013263 (2018)","journal-title":"Arch. Endocrinol. Metab"},{"key":"2953_CR14","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1007\/BF03346388","volume":"31","author":"L Vilar","year":"2008","unstructured":"L. Vilar, M.C. Freitas, L.A. Naves, L.A. Casulari, M. Azevedo, R. Montenegro, A.I. Barros, M. Faria, G.C. Nascimento, J.G. Lima, L.H. N\u00f3brega, T.P. Cruz, A. Mota, A. Ramos, A. Violante, A. Lamounier Filho, M.R. Gadelha, M.A. Czepielewski, A. Glezer, M.D. Bronstein, Diagnosis and management of hyperprolactinemia: results of a Brazilian multicenter study with 1234 patients. J. Endocrinol. Invest. 31, 436\u2013444 (2008)","journal-title":"J. Endocrinol. Invest."},{"key":"2953_CR15","first-page":"S11","volume":"61","author":"L Vilar","year":"2017","unstructured":"L. Vilar, J.L. Albuquerque, C.F. Vilar, L.A. Ferreira, I.R.A. Cardoso, I.S. Inacio, Demographic, clinical, and laboratorial features of 770 patients with hyperprolactinemia. Arch. Endocrinol. Metab. 61, S11 (2017)","journal-title":"Arch. Endocrinol. Metab."},{"key":"2953_CR16","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1530\/eje.0.1470077","volume":"147","author":"M Doknic","year":"2002","unstructured":"M. Doknic, S. Pekic, M. Zarkovic, M. Medic-Stojanoska, C. Dieguez, F. Casanueva, V. Popovic, Dopaminergic tone and obesity: an insight from prolactinomas treated with bromocriptine. Eur. J. Endocrinol 147, 77\u201384 (2002)","journal-title":"Eur. J. Endocrinol"},{"key":"2953_CR17","doi-asserted-by":"publisher","first-page":"2","DOI":"10.11604\/pamj.2020.35.2.12883","volume":"35","author":"MCE Etoga","year":"2020","unstructured":"M.C.E. Etoga, E. Sobngwi, P. Ngoune, E. Doh, F.M. Mekobe, N. Mbango-Ekouta, M. Dehayem, P. Foumane, J.C. Mbanya, Clinical profile and early therapeutic response to cabergoline of patients with hyperprolactinemia in a Cameroonian population. Pan. Afr. Med. J 35, 2 (2020)","journal-title":"Pan. Afr. Med. J"},{"key":"2953_CR18","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1530\/EJE-21-0561","volume":"185","author":"B Biagetti","year":"2021","unstructured":"B. Biagetti, S. Sarria-Estrada, Y.K. Ng-Wong, E. Martinez-Saez, A. Caster\u00e0s, E. Cordero Asanza, I. Hernandez, M. Giralt-Arnaiz, R. Sim\u00f2, Shrinkage by the third month predicts long-term response of macroprolactinoma after cabergoline. Eur. J. Endocrinol 185, 587\u2013595 (2021)","journal-title":"Eur. J. Endocrinol"},{"key":"2953_CR19","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.4158\/EP15804.OR","volume":"21","author":"A Tirosh","year":"2015","unstructured":"A. Tirosh, C. Benbassat, I. Shimon, Short-term decline in prolactin concentrations can predict future prolactin normalization, tumor shrinkage, and time to remission in men with macroprolactinomas. Endocr. Pract. 21, 1240\u20131247 (2015)","journal-title":"Endocr. Pract."},{"key":"2953_CR20","doi-asserted-by":"crossref","unstructured":"Hage C., Salvatori R. Predictors of the response to dopaminergic therapy in patients with prolactinoma. J. Clin. Endocrinol. Metab. 105 (2020)","DOI":"10.1210\/clinem\/dgaa652"},{"key":"2953_CR21","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1530\/EJE-19-0753","volume":"182","author":"D Kim","year":"2020","unstructured":"D. Kim, C.R. Ku, K. Kim, H. Jung, E.J. Lee, Prolactin \u22641 ng\/mL predicts macroprolactinoma reduction after cabergoline therapy. Eur. J. Endocrinol 182, 177\u2013183 (2020)","journal-title":"Eur. J. Endocrinol"},{"key":"2953_CR22","doi-asserted-by":"publisher","first-page":"3709","DOI":"10.1210\/jc.2016-2008","volume":"10","author":"A Faje","year":"2016","unstructured":"A. Faje, P. Chunharojrith, J. Nency, B.M. Biller, B. Swearingen, A. Klibanski, Dopamine Agonists Can Reduce Cystic Prolactinomas. J. Clin. Endocrinol. Metab. 10, 3709\u20133715 (2016)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2953_CR23","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1677\/ERC-08-0181","volume":"15","author":"A Colao","year":"2008","unstructured":"A. Colao, C. Di Somma, R. Pivonello, A. Faggiano, G. Lombardi, S. Savastano, Medical therapy for clinically non-functioning pituitary adenomas. Endocr. Relat. Cancer. 15, 905\u2013915 (2008)","journal-title":"Endocr. Relat. Cancer."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-021-02953-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-021-02953-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-021-02953-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T14:12:52Z","timestamp":1646143972000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-021-02953-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,30]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["2953"],"URL":"https:\/\/doi.org\/10.1007\/s12020-021-02953-1","relation":{},"ISSN":["1355-008X","1559-0100"],"issn-type":[{"value":"1355-008X","type":"print"},{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,30]]},"assertion":[{"value":"22 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors have no financial or nonfinancial interests that are directly or indirectly related to the work submitted. This work was approved by the local IRB, and no consent form for subjects was deemed necessary due to its retrospective nature.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}